Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Schmid, D ^a   Jarvis, G E ^b   Fay, F ^a   Small, D M ^a   Greene, M K ^a   Majkut, J ^a   Spence, S ^a   McLaughlin, K M ^a   McCloskey, K D ^a   Johnston, P G ^a   Kissenpfennig, A ^a   Longley, D B ^a   Scott, C J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CAMPTOTHECIN; MACROGOL; NANOPARTICLE; ABT-737; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; NITROPHENOL; PIPERAZINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG POTENTIATION; GASTROINTESTINAL TOXICITY; HCT116 CELL LINE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR XENOGRAFT; ANIMAL; C57BL MOUSE; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG EFFECTS; EVALUATION STUDY; PATHOPHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIPHENYL COMPOUNDS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG COMPOUNDING; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; NITROPHENOLS; PIPERAZINES; SULFONAMIDES; THROMBOCYTOPENIA;

EID: 84928009380     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.413     Document Type: Article

References (52)

1. American Cancer Society. Colorectal Cancer-Facts and Figures 2011-2013. American Cancer Society: Atlanta, GA, USA, 2011.
2. Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 2013; 17: 61-75.
3. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
4. Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 2011; 10: 2340-2349.
5. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-916.
6. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012; 18: 3163-3169.
7. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
8. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
9. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14: 943-951.
10. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006; 6: 789-802.
11. Juvekar AS, Thompson J, Stewart CF, Houghton PJ. Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs In: Adams VR, Burke TG eds Camptothecins in Cancer Therapy. Humana Press Inc: Totowa, NJ, USA, 2005; pp 127-152.
12. Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs 2011; 71: 2531-2558.
13. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11: 812-818.
14. Eliasof S, Lazarus D, Peters CG, Case RI, Cole RO, Hwang J et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci USA 2013; 110: 15127-15132.
15. McCarron PA, Marouf WM, Quinn DJ, Fay F, Burden RE, Olwill SA et al. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug Chem 2008; 19: 1561-1569.
16. Fay F, McLaughlin KM, Small DM, Fennell DA, Johnston PG, Longley DB et al. Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials 2011; 32: 8645-8653.
17. Abdelghany SM, Quinn DJ, Ingram RJ, Gilmore BF, Donnelly RF, Taggart CC et al. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. Int J Nanomedicine 2012; 7: 4053-4063.
18. Moghimi SM, Hunter AC, Murray JC.. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53: 283-318.
19. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005; 17: 631-636.
20. Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death Differ 2006; 13: 1256-1259.
21. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA et al. 'Seed' analysis of offtarget siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007; 26: 3972-3979.
22. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-388.
23. Safa AR. c-FLIP, a master antiapoptotic regulator. Exp Oncol 2012; 34: 176-184.
24. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25: 838-848.
25. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 2005; 4: 2026-2036.
26. Sempf K, Arrey T, Gelperina S, Schorge T, Meyer B, Karas M et al. Adsorption of plasma proteins on uncoated PLGA nanoparticles. Eur J Pharm Biopharm 2013; 85: 53-60.
27. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5: 505-515.
28. Sheng Y, Yuan Y, Liu C, Tao X, Shan X, Xu F. In vitro macrophage uptake and in vivo biodistribution of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content. J Mater Sci Mater Med 2009; 20:1881-1891.
29. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S et al. 'Stealth' coronacore nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000; 18: 301-313.
30. Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 2012; 1: 10.
31. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010; 2: 51-63.
32. Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA et al. First-inhuman phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 2013; 31: 986-1000.
33. Infante JR, Keedy VL, Jones SF, Zamboni WC, Chan E, Bendell JC et al. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012; 70: 699-705.
34. Hamaguchi T, Doi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res 2010; 16: 5058-5066.
35. Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ et al. Bcl-xLinhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118: 1663-1674.
36. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
37. Schulze-Bergkamen H, Ehrenberg R, Hickmann L, Vick B, Urbanik T, Schimanski CC et al. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol 2008; 14: 3829-3840.
38. Maurer CA, Friess H, Buhler SS, Wahl BR, Graber H, Zimmermann A et al. Apoptosis inhibiting factor Bcl-xL might be the crucial member of the Bcl-2 gene family in colorectal cancer. Dig Dis Sci 1998; 43: 2641-2648.
39. Okumura K, Huang S, Sinicrope FA. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res 2008; 14: 8132-8142.
40. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008; 68: 2944-2951.
41. Nakajima W, Hicks MA, Tanaka N, Krystal GW, Harada H. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Cell Death Dis 2014; 5: e1052.
42. McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010; 16: 3442-3451.
43. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F et al. Sensitization of BCL-2- expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA 2011; 109: 2766-2771.
44. Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB et al. The Bcl-2/ Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007; 13: 7191-7198.
45. Raats DA, de Bruijn MT, Steller EJ, Emmink BL, Borel-Rinkes IH, Kranenburg O. Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737. Cell Oncol (Dordr) 2011; 34: 307-313.
46. Wang H, Zhao Y, Wu Y, Hu YL, Nan K, Nie G et al. Enhanced antitumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011; 32: 8281-8290.
47. Valencia PM, Pridgen EM, Perea B, Gadde S, Sweeney C, Kantoff PW et al. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond) 2013; 8: 687-698.
48. Jarvis GE, Atkinson BT, Frampton J, Watson SP. Thrombin-induced conversion of fibrinogen to fibrin results in rapid platelet trapping which is not dependent on platelet activation or GPIb. Br J Pharmacol 2003; 138: 574-583.
49. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68: 2321-2328.
50. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
51. Schwarz G. Estimating the dimension of a model. Ann Stat 1978; 6: 461-464.
52. Spalding MD, Jarvis GE. The impact of the 1998 coral mortality on reef fish communities in the Seychelles. Mar Pollut Bull 2002; 44: 309-321.